Sales results of TOPAMAX?® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL?® (risperidone), an antipsychotic medication, were negatively impacted by continued generic competition.

During the quarter, the Company acquired RespiVert Ltd., a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.

Additionally the Company signed an exclusive agreement with Diamyd Medical AB to develop and commercialize the GAD65 antigen-based diabetes therapy.

Worldwide Medical Devices and Diagnostics sales of $6.1 billion for the second quarter represented an increase of 4.1% versus the prior year consisting of an operational increase of 3.5% and a positive currency impact of 0.6%. Domestic sales increased 3.2%; international sales increased 5.0%, which reflected an operational increase of 3.9% and a positive currency impact of 1.1%.

Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.

During the quarter, the Company received clearance from the United States Food and Drug Administration to market narafilcon B, the first and only silicone hydrogel daily disposable contact lens in the United States, which will be marketed under the name 1-DAY ACUVUE?®  TruEye?„? Brand Contact Lenses.

In July, the Company entered into a definitive agreement to acquire Micrus Endovascular, a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke. Also in July, Ethicon Endo-Surgery completed the divestiture of its Breast Care business to Devicor Medical Products, Inc.

SOURCE Johnson & Johnson